Since that time, several clinical trials have proven the efficacy of trastuzumab, also resulting in establishing routine HER-2 testing in breast cancer patients and dramatically changing the therapeutic approach to those carrying the mutation. The gene discussed is ERBB2; the disease is breast carcinoma.